Andrzej Jakubowiak to Clinical Trials as Topic
This is a "connection" page, showing publications Andrzej Jakubowiak has written about Clinical Trials as Topic.
Connection Strength
0.414
-
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020 09; 34(9):2430-2440.
Score: 0.120
-
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014 Sep; 99(9):e162-4.
Score: 0.081
-
Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview. Cancer Treat Rev. 2014 Jul; 40(6):781-90.
Score: 0.079
-
Evolving strategies in the initial treatment of multiple myeloma. Semin Oncol. 2013 Oct; 40(5):592-601.
Score: 0.077
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30.
Score: 0.031
-
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(2):222-9.
Score: 0.013
-
The research mission in myeloma. Leukemia. 2009 Feb; 23(2):422-3; author reply 423-4.
Score: 0.013